Recombinant Human IGFBP-6 protein (His Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human IGFBP-6 protein (His Tag) (Eg3437)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg3437

---

Validation Data Gallery

• 

  Purity of Recombinant Human IGFBP-6 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human IGFBP-6 protein Arg28-Gly240 (Accession# P24592) with a His tag at the C-terminus.
• GeneID: 3489
• Accession: P24592
• PredictedSize: 23.7 kDa
• SDS-PAGE: 27-35kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

IGFBP-6 (Insulin-like Growth Factor Binding Protein-6) is a member of the insulin-like growth factor binding protein family, which plays a crucial role in regulating the actions of insulin-like growth factors (IGFs). IGFBP-6 is involved in the immune response, particularly in human dendritic cells (DCs), and has been implicated in different human diseases. IGFBP-6 has been implicated in the biology of tumors, playing a controversial role. It is considered a protein of interest in cancer development and progression, with direct relations to immunological functions and inflammation activities in glioma, potentially serving as a therapeutic target for glioma immunotherapy

References:

1. Leon A Bach. et al.(2015). J Cell Commun Signal. 9(2):189–200.
2. Arcangelo Liso. et al. (2022). Int J Mol Sci. 23(8):4358.